ARCHIVES

NCI Beings Accelerated Review Of R01s That just Miss Payline

This article is from The Cancer Letter archive.

Vol. 22 No. 13 | March 29, 1996

Download PDF Visit The Full Archive

Related Articles

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014

Committee Drafts QRA Definition

November 19, 1982

FDA Orders More Changes In ESA Label,

August 8, 2008

Centers: Bookman Leaves Fox Chase for Arizona

September 11, 2009

Hybridoma Cell Lines Available from NCI

September 3, 1982

New Breast Cancer Therapies Move Into General Practice; Fisher, Miami Plan Segmental Trials

February 13, 1976